COMPANY PROFILE / #2783
Genomenon
Ann Arbor, MIVenture Capital-Backed
OVERVIEW
Developer of genome interpretation software designed to improve cancer diagnosis and treatment. The company's software offers a set of diagnostic and discovery tools to identify disease-causing genomic variants and assists in treating cancer and other heritable diseases, enabling physicians to improve patient outcomes.
已融资42.78
最新估值74.03
员工数136
成立年份2014
公司概况
- Companies
- Genomenon
- Description
- Developer of genome interpretation software designed to improve cancer diagnosis and treatment. The company's software offers a set of diagnostic and discovery tools to identify disease-causing genomic variants and assists in treating cancer and other heritable diseases, enabling physicians to improve patient outcomes.
- Website
- www.genomenon.com
- HQ Location
- Ann Arbor, MI
- Year Founded
- 2014
- Keywords
- cancer diagnosis product, exome sequencing, generation sequencing, genetics testing, genome interpretation software, pharmaceutical instruments
- Competitors
- Congenica, Scipher Medicine, Phosphorus (Decision/Risk Analysis), Personal Genome Diagnostics, PierianDx, Foundation Medicine, Genialis, Partek, Strand (Biotechnology), Deep Genomics, Genoox, MedGenome Labs, Second Genome, Adaptive Biotechnologies, Myriad Genetics, Genotypic Technology, Knome (US), Genuity Science, DNAnexus, Eagle Genomics, Station X, PointCross Life Sciences, Cancer Genetics India, Edico Genome, Gene By Gene, Nebula Genomics, InterpretOmics, NanoString Technologies
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 42.78
- First Financing Date
- —
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 30-Jul-2026
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 6.03
- Last Financing Valuation
- 74.03
- Last Financing Status
- Completed
- Last Known Valuation
- 74.03
- Last Known Valuation Date
- 30-Jul-2026
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 77.56
- Valuation Estimate Growth Rate
- 4.77%
- Active Investors
- Ann Arbor SPARK, Atain Insurance Company, Beringea, BroadOak Capital Partners, Danmar Capital, Great Lakes Entrepreneurs Quest, Green Park & Golf Ventures, H.W. Kaufman Financial Group, Innovation Partnerships, Invest Detroit, Invest Detroit Ventures, Invest Michigan, IrishAngels, Michigan Angel Fund, Michigan Biomedical Venture Fund, Michigan Rise, MINTS (Michigan Investment in New Technology Startups), Northern Michigan Angels, P93 Ventures, Red Cedar Ventures, Small Business Innovation Research and Small Business Technology Transfer Programs, Sorin Capital Funds, Spring Mountain Capital, The 4100 Group, The National Human Genome Research Institute, Three Leaf Ventures
- # Active Investors
- 26
- Acquirers
- —
团队与联系人
- Employees
- 136
- Employee Growth %
- -9.33%
- Employee History
- 2026: 136, 2025: 150, 2024: 170, 2023: 68, 2022: 44, 2021: 37, 2020: 27, 2019: 23 E, 2018: 20 E, 2017: 16 E, 2016: 13 E, 2015: 9
- Primary Contact
- Mark Kiel
- Primary Contact Title
- Co-Founder, Chief Science Officer & Board Member
- Primary Contact Email
- kiel@genomenon.com
- Primary Contact Phone
- +1 (734) 794-3075
增长与经营
- Revenue
- 14.20
- Revenue Growth %
- —
- Growth Rate
- -0.24%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 10
- Size Multiple
- 19.29x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 97
- Majestic Referring Domains
- 561
- SimilarWeb Unique Visitors
- 1,048
- SimilarWeb Unique Visitors Change
- -314
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 13%
- Success Probability Over Time – 3 Year
- 29%
- Success Probability Over Time – 5 Year
- 51%
记录来源：public.companies · 原始序号 #2783 · 所有字段均按数据库原值展示。